{"topic_id":"ade_grapiprant_adverse_events","category":"ade","context":"---\ntopic_id: ade_grapiprant\ncategory: ade\ntitle: \"FDA ADE reports for Grapiprant — total reports, species & reaction breakdown\"\nlang: en\nsource: \"openFDA animalandveterinary/event.json (FDA CVM adverse event reports), pulled 2026-07-21\"\nsource_file: pdf-raw/ade/ade_active_ingredients_2026-07-21.json\ndate_parsed: 2026-07-21\ntokens_estimated: 200\nverification:\n  method: substring_match\n  claims: 15\n  passed: 15\n  date: 2026-07-21\n---\n\n# Grapiprant — FDA Animal & Veterinary Adverse Event (ADE) Reports\n\nSource: openFDA `animalandveterinary/event.json`, the FDA Center for Veterinary Medicine (CVM) adverse event report database. Data pulled 2026-07-21. Counts are report-level: one report may list multiple reactions and multiple animals, so figures are not additive and do not imply causation. Grapiprant is a veterinary active ingredient.\n\n## Total reports\nGrapiprant: 8225\n\n## Reports by species (top entries)\n- Dog 7556\n- Cat 15\n- Human 13\n- Pig 1\n\n## Top reported reactions (VEDDRA terms, top entries)\n- Vomiting 1429\n- Diarrhoea 1257\n- Lack of efficacy - NOS 961\n- Lethargy (see also Central nervous system depression in 'Neurological') 659\n- Elevated alanine aminotransferase (ALT) 509\n- Death by euthanasia 479\n- Not eating 468\n- Decreased appetite 430\n- Bloody diarrhoea 392\n- Tablets, Abnormal 369\n\n\"Lack of efficacy\" terms denote product-performance reports, not adverse reactions.\n\nSource JSON: `pdf-raw/ade/ade_active_ingredients_2026-07-21.json` (openFDA animalandveterinary/event.json, pulled 2026-07-21).\n","sources":[],"tokens_estimated":200,"generated_at":null,"tip":"Use /api/v1/topics to discover more topics. /api/v1/nutrient for precise single-point queries. /api/v1/cross_compare for 2-3 standard comparisons."}